Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 10/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21608307 | 0.82 | DRD1 (0.38) | DRD1ROCK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL4550230 | 0.75 | PDE3B (0.58) | DRD1PDE3BPDE3APIK3CDTRPA1 | |
| SCHEMBL23877021 | 0.74 | TRPA1 (0.45) | DRD1ROCK1PIK3CDPIK3CAPIK3CB | |
| Hydrochloric Acid SCHEMBL29243587 | 0.73 | TRPA1 (0.44) | DRD1ROCK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL5259159 | 0.72 | NUDT1 (0.39) | DRD1ROCK1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL14062242 | 0.71 | PIK3C3 (0.49) | PIK3CATRPA1NUDT1 | |
| SCHEMBL31098989 | 0.70 | TTBK1 (0.64) | — | |
| SCHEMBL14059926 | 0.69 | NUDT1 (0.40) | DRD1ROCK1TRPA1NUDT1 | |
| SCHEMBL3887252 | 0.68 | NUDT1 (0.51) | NUDT1 | |
| SCHEMBL15753484 | 0.68 | HPGDS (0.47) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-05-06 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243533-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DRD1 4678/4885PDE3B 4226/4885PDE3A 4006/4885 |
| US-20210130352-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | DRD1 4678/4885PDE3B 4226/4885PDE3A 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.